New tests launched in May - Insights
In May 2023, Mayo Clinic Laboratories announced 22 new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
New tests launched in October - Insights
In October 2021, Mayo Clinic Laboratories announced eleven new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
New tests launched in January - Insights
In January 2022, Mayo Clinic Laboratories announced twenty five new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
Embracing the transformative power of digital pathology - Insights
Mayo Clinic is harnessing the extraordinary potential of digital pathology through a robust initiative that’s using the technology to enhance patient care. Mayo’s Dermatology Department is an early adopter, and clinicians, students, and...
Membranous nephropathy assay: PMND1 - Insights
John Lieske, M.D., describes Mayo Clinic Laboratories' new test for primary membranous nephropathy. PMND1 is a diagnostic cascade that provides a cost-effective approach to detecting antigens known to cause membranous nephropathy — a...
FDA-approved test expands options for Alzheimer's disease - Insights
Joshua Bornhorst, Ph.D., describes the new, FDA-approved Alzheimer's disease (AD) test and how it differs from Mayo Clinic Laboratories' existing AD evaluation. The laboratory will offer both tests, to ensure flexibility and options for...
IDH assay facilitates timelier leukemia treatment: Rong He, M.D. - Insights
In this test-specific episode of the "Answers From the Lab" podcast, Rong He, M.D., explains how Mayo Clinic Laboratories' IDHQ test improves upon next generation sequencing for assessing AML treatment options.
Chromium and Cobalt - Insights
Paul Jannetto, Ph.D., describes Mayo Clinic Laboratories' synovial fluid testing for patients with symptoms of failed hip arthroplasty. The Food and Drug Administration recommends testing for elevated chromium and cobalt, which can indicate...
Monoclonal Gammopathy Informative Cases - Insights
Mayo Clinic Laboratories provides evaluation and consultation for the diagnosis and treatment of patients with hereditary and acquired hematologic disorders.
PIK3CA assay guides treatment of progressing breast cancer - Insights
Katherine Geiersbach, M.D., explains how Mayo Clinic Laboratories' PIK3CA assay informs breast cancer treatment. The assay identifies patients eligible for a certain second-line therapy when initial treatment has failed.